pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer
American Society of Clinical Oncology
FDA Veteran Paz Vellanki, MD, joins Precision to become one of 3 ex-FDA oncology leaders supporting clients
Peer-reviewed articles and conference poster presentations
Poster
Download Poster
Poster
Download Poster
Poster
Download Poster
Poster
Download Poster
Poster
Download Poster